Efficacy and tolerability of amifostine in elderly cancer patients - Wikidata - wikimedia - TriplyDB

Efficacy and tolerability of amifostine in elderly cancer patients

Efficacy and tolerability of amifostine in elderly cancer patients

http://www.wikidata.org/entity/Q33738758

about

Preparation of amifostine polylactide-co-glycolide microspheres and its irradiation protective to mouse through oral administration.

P2860

Q44365761-990C7BCB-3415-4AA9-A543-9959F96AC787

P2860

Efficacy and tolerability of amifostine in elderly cancer patients

http://www.wikidata.org/entity/Q33738758

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Efficacy and tolerability of amifostine in elderly cancer patients

@ast

Efficacy and tolerability of amifostine in elderly cancer patients

@en

type

label

Efficacy and tolerability of amifostine in elderly cancer patients

@ast

Efficacy and tolerability of amifostine in elderly cancer patients

@en

prefLabel

Efficacy and tolerability of amifostine in elderly cancer patients

@ast

Efficacy and tolerability of amifostine in elderly cancer patients

@en

P1433

Q33738758-726C6885-14B1-4717-929E-F2DA578209A2

P1476

Q33738758-457BF90B-882B-4C29-AB98-C6CEB4558363

P2093

Q33738758-29965ED1-EEC2-411E-9B7E-C8015BF1926A

Q33738758-B0A03758-C029-4E81-A2DB-2EE27404C70F

Q33738758-D4F931A5-064C-4563-ACD4-2DC6EF61EF39

Q33738758-E54AAAFE-672E-4818-AA3D-F20B5058C59C

Q33738758-F14E3FE7-7E64-4D3C-B67F-54C11607A337

Q33738758-F34C16F0-D6E3-45D8-A6B2-9E859BF57468

P2860

Q33738758-0A4A67F5-00DA-4C22-8B6B-6A04FA0ACEF6

Q33738758-24F82829-F4B9-4345-BB37-1522FC4E9A68

Q33738758-28DDD407-63DA-4974-B385-80EDB82A0ABF

Q33738758-37A5CCA6-0E54-496F-9562-74A60D01DA65

Q33738758-437C0BCC-74FD-4F31-B3A7-A538F4D9BBB8

Q33738758-450FE3FA-B288-44AE-914A-4D5FED68DF24

Q33738758-471EB0F2-2050-4D68-BA56-14AB21A7BAD3

Q33738758-66CC93A4-7677-4E79-B709-B73C75D1EA57

Q33738758-7B9DF940-8CD8-43BE-85FD-C9027C69CB3E

Q33738758-865CA2F7-838B-4229-9005-FED4947D25AF

P304

Q33738758-997EBC38-29FC-428D-96C0-562A38480C1E

P31

Q33738758-76647603-A2D3-4F40-906E-D590C9051537

P356

Q33738758-B24B2680-7C9A-4E7C-944B-D0BFC45F03B4

P433

Q33738758-29BE4158-A764-4A56-886F-4880D8361C36

P478

Q33738758-D4F3798D-7F0F-4D55-9BED-0136BAACAEC6

P577

Q33738758-CFCE9DF2-BEB3-4CD9-BE8A-0C855D64B751

P698

Q33738758-E85475D4-3EBF-42A4-908D-9A7F69D2DDA5

P932

Q33738758-0E6C8451-5D7C-41BD-97AB-F68C584D1B9F

P356

S0011-393X(04)90011-2

P1433

Current Therapeutic Research

P1476

Efficacy and tolerability of amifostine in elderly cancer patients

@en

P2093

Gurhan Kadikoylu

http://www.w3.org/2001/XMLSchema#string

Harun Akar

http://www.w3.org/2001/XMLSchema#string

Irfan Yavasoglu

http://www.w3.org/2001/XMLSchema#string

Nezih Meydan

http://www.w3.org/2001/XMLSchema#string

Sabri Barutca

http://www.w3.org/2001/XMLSchema#string

Zahit Bolaman

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.

Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

Anticancer drug-induced kidney disorders.

A risk-benefit assessment of amifostine in cytoprotection.

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

Amifostine: drug profile and nursing implications of the first pancytoprotectant.

Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.

Dosing considerations with amifostine: a review of the literature and clinical experience.

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

P304

113-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0011-393X(04)90011-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24936110

http://www.w3.org/2001/XMLSchema#string

P932

4052963

http://www.w3.org/2001/XMLSchema#string